Not an actual patient.

SET YOUR SIGHTS ON FLEXIBILITY, WITH 4 DOSING OPTIONS BASED ON YOUR PATIENTS’ NEEDS

ELIGARD^® comes in 1-, 3-, 4-, and 6-month doses, allowing for as few as 2 injections per year—which can align with your patients’ scheduled checkups¹

The unique delivery technology of ELIGARD enables one of the smallest injection volumes available—helping provide less discomfort to your patients²

*Approximate dosing volume.

ELIGARD IS THE ONLY SUBCUTANEOUS ADT WITH 4 DOSING OPTIONS, GIVING YOU THE FLEXIBILITY TO MEET THE NEEDS OF A DIVERSE RANGE OF PATIENTS^1,2

ELIGARD OPTIMIZES PATIENT EXPERIENCE WITH 
SUBCUTANEOUS INJECTION²

Subcutaneous (SC) injections provide flexibility

The benefits of ELIGARD and SC injection²

Large surface area

Can be administered anywhere with sufficient SC tissue, not just the abdomen
Suitable for patients with lower muscle mass

Patient friendly

Minimally invasive, avoids local muscle soreness, and appropriate for patients with mobility challenges, including wheelchair users
Flexibility in site of care, since it can be administered in semiprivate settings

Reduced risk of complications

Low likelihood of bone and nerve damage and safe for patients on anticoagulants

ELIGARD IS THE ONLY SUBCUTANEOUS ADT WITH MULTIPLE INJECTION SITE OPTIONS²

Plan your patient's treatment schedule

Dosing Calculator

Use the Dosing Calculator tool to instantly see when your patient is due for their next dose by inputting the date of their latest treatment and prescribed dose.

FDA approval of the ELIGARD product was based on studies utilizing a 28-day month dosing interval. This dosing calculator is for informational purposes only. Final dosing timing decision is up to the physician’s discretion.

GET RELIABLE T SUPPRESSION WITH ELIGARD’S EXTENDED-RELEASE TECHNOLOGY

ADT, androgen deprivation therapy.

References: 1. ELIGARD (leuprolide acetate). Prescribing Information. Tolmar, Inc. 2024. 2. Prettyman J, Engel L, Boldt-Houle DM, Atkinson S, Wilt W. Personalizing treatment in the delivery of care by nurses to patients with prostate cancer. Urologic Nursing. 2019;39(2):83-99.

Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD^® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

To report SUSPECTED ADVERSE REACTIONS, contact Tolmar at 1-888-354-4273 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for ELIGARD or full Prescribing Information for ELIGARD Pre-Connected Syringe System.

SET YOUR SIGHTS ON FLEXIBILITY, WITH 4 DOSING OPTIONS BASED ON YOUR PATIENTS’ NEEDS

ELIGARD OPTIMIZES PATIENT EXPERIENCE WITH SUBCUTANEOUS INJECTION2

The benefits of ELIGARD and SC injection2